About Half of Traditional Medicare Beneficiaries Are in ACOs, Says CMS
CMS said in a news release today that 13.7 million beneficiaries are in accountable care organizations (ACOs) and that a total of 480 ACOs are participating in the Medicare Shared Savings Program (MSSP).
Medicare accountable care organizations (ACOs) now include 13.7 million beneficiaries, or nearly half of the people in traditional Medicare, the Centers for Medicare & Medicaid Services (CMS) said today as part of announcement about ACO growth and enrollment.
Sixty-nine new ACOs are now participating in the Medicare Shared Saving Program (MSSP), CMS’ largest ACO program, according to the CMS news release. Nineteen of those newcomers are in a new payment option that includes advance investment payments for caring for beneficiaries in underserved populations
Counting the 71 ACOs that renewed their participation in the program, there are now 480 ACOs in MSSP, according to CMS.
The agency said that an additional 245 organizations are continuing to participate in two other valued-based programs, the ACO Realizing Equity, Access, and Community Health (ACO REACH) and the Kidney Care Choices (KCC) models.
The 19 ACOs receiving investment payments are required to invest in healthcare infrastructure and staffing that is supposed to improve healthcare for underserved beneficiaries. Hiring community health workers and utilizing health assessment and screening tools are among the steps they are taking to accomplish that goal, according to the news release.
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Phase 3 Trial of Vertex’s Islet Cell Therapy for Type 1 Diabetes Under Way
April 23rd 2025Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if approved, would be the second cell therapy for type 1 diabetes.
Read More
